Data Readout

Immix's NXC-201 posts 95% CR rate in AL amyloidosis ahead of March 2027 update

Nineteen of 20 evaluable patients reached complete response in the CAR-T trial, setting up 1-year follow-up data Immix says will support a BLA filing.

By AppliedXLJuly 13, 2026Trial NCT06097832

Executive Summary

Immix Biopharma disclosed that nearly all evaluable patients in its lead CAR-T trial for a rare, organ-destroying blood disorder reached complete remission, with no relapses observed among responders.
The company is positioning a further data update, expected around a year after dosing, as the evidence base for a marketing application, raising the bar for what that update needs to show.
No other industry-sponsored trial combines this cell-therapy target with this indication, so the readout will be judged against precedent from the same modality in the adjacent blood cancer where it originated, not against a like-for-like rival.
Durability in a larger, longer-followed cohort, not the initial response rate, is what would validate the sponsor's plan to move directly toward registration.

The disclosure

Immix Biopharma said on May 21, 2026 that all four previously MRD-negative patients in NEXICART-2 have since converted to complete response, pushing the trial's complete response rate to 95%, or 19 of the first 20 patients. All complete responses were reached within one year of dosing, and the company reported no relapses to date among patients who achieved that response. Patients subsequently enrolled and evaluated for minimal residual disease were MRD-negative at one month. The population had received a median of four prior lines of therapy, with NXC-201 given as a fifth-line treatment. Immix

Probability of Success

Endpoint Met75%

Completes82%

Clinical Significance19%

Regulatory59%

The trial

NEXICART-2 (NCT06097832) is a Phase 1/2, U.S.-based, single-arm study of NXC-201, a BCMA-targeted CAR-T cell therapy, in adults with relapsed or refractory AL amyloidosis who have measurable hematologic disease and symptomatic organ involvement. The registry lists a target enrollment of 40 patients, recruiting status, and a primary completion date of December 1, 2026, after that date slipped 12 months from an original December 2025 target in an April 2024 amendment. The trial's registered primary endpoints are safety measures: treatment-related adverse events, adverse events by severity, and confirmation of the maximum tolerated dose and recommended Phase 2 dose, rather than the response-rate figures the company has been disclosing. NCT06097832

The next update

Immix's president and chief financial officer, Gabriel Morris, said the company plans to present updated NEXICART-2 data in September 2026, and by the end of March 2027 expects to present 1-year follow-up data on enrolled patients that it expects will support a biologics license application and commercial launch. That March 2027 window is the catalyst this story tracks: a maturation of the same complete-response dataset over a longer follow-up period and, potentially, a larger patient set than the 20 patients described so far. Immix

Competitive and regulatory context

No other industry-sponsored trial pairs a BCMA-targeted therapy with AL amyloidosis, based on a scan of competitive trials in the indication and target. The nearest precedent for the modality comes from BCMA-targeted CAR-T programs in multiple myeloma, including Janssen's ciltacabtagene autoleucel and Bristol Myers Squibb's idecabtagene vicleucel, both approved cell therapies in a related plasma-cell disease that established the modality's activity against BCMA-expressing clones. NXC-201 holds FDA Orphan Drug Designation for AL amyloidosis and multiple myeloma and Regenerative Medicine Advanced Therapy designation, along with EMA Orphan Drug Designation, positioning the program for expedited regulatory engagement ahead of any filing. Immix

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.